ZNF154 and cancer: These findings, in comparison to our previous measurements of ZNF154 cfDNA methylation (i.e., AUC = 0.85 at late stage), indicate that ZNF154 has potential to outperform even the most common cancer-associated mutations when used to classify plasma samples from individuals with and without cancer.